Speaker illustration

Doctor Brendon Neuen

The George Institute for Global Health, Sydney (Australia)

Dr Brendon Neuen is a Nephrologist and Director of the Kidney Trials Unit at Royal North Shore Hospital, and Senior Research Fellow at The George Institute for Global Health in Sydney, Australia. He is widely recognised for his expertise in cardio-renal-metabolic medicine and is involved in the leadership of several large-scale trials evaluating therapeutic strategies to slow CKD progression and reduce cardiovascular risk. Dr Neuen established the SGLT2 Meta-Analysis Cardio-Renal Trialists' Consortium, bringing together data on >90,000 patients to better understand the effects of this class of medicines in different types of patients. His work has directly informed more than 25 major international and national guidelines, position papers and scientific statements which define optimal care for people with type 2 diabetes and kidney disease including the KDIGO guidelines and American Diabetes Association Standards of Care.

Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: Insights from the CREDENCE trial

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacotherapy

Session: Congress committee e-posters choice in preventive cardiology and special populations


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb